Cash/Burn From SEC Filing For Period: 

DVAX

Dynavax Technologies

Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines.

Cash

$200.7M

Burn Rate

$134.4M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Heplisav-B

Hepatitis B Vaccine

Quarterly Sales (Approved)

October 23, 2020 (Est)

SARS-CoV-2 Inactivated Vaccine (with Sinovac)

COVID-19 Vaccine

Phase 3 Readout

TBD

COVID-19 Vaccine (with Medicago)

COVID-19 Vaccine

Phase 1 (Preliminary safety and immunogenicity results)

October 2020 (Est)

COVID-19 S-Trimer (with Clover Biopharmaceuticals)

COVID-19 Vaccine

Phase 1

TBD

Vaccine Candidate (with Valneva)

COVID-19 Vaccine

Pre-clinical

TBD

Vaccine Candidate (with Coalition for Epidemic Preparedness Innovations (CEPI) and Queensland)

COVID-19 Vaccine

Pre-Clinical

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon